United States· US:50090-7919_3cc5ee17-3376-493a-8146-42df66edb945
Shingrix
A medicinal product containing recombinant varicella zoster virus glycoprotein e antigen, registered in United States by A-S Medication Solutions.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN
- Manufacturer
- A-S Medication Solutions
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1150090791901 mL in 1 KIT (50090-7919-0)
- ndc1150090-7919-0
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ef110125-56a8-48f0-b898-37fa3e705ab8 GET /v1/drugs/ef110125-56a8-48f0-b898-37fa3e705ab8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAMUSCULAR",
"source": "ndc",
"strength": "50",
"substance": "RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN",
"productndc": "50090-7919",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "ug/.5mL",
"application_number": "BLA125614",
"marketing_category": "BLA"
}See everything about recombinant varicella zoster virus glycoprotein e antigen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.